Glaukos Corporation vs Johnson & Johnson — Stock Comparison
Q·Score Breakdown
5.8
Neutral
Overall
7.1
Bullish
Quality
Health
Growth
Valuation
Sentiment
GKOS
Clean balance sheet with low leverage (0.2× debt-to-equity).
⚠ currently unprofitable (-34% margin).
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
BUY
Target $151.08 (+7.7%)
12 analysts
BUY
Target $252.42 (+11.1%)
24 analysts
Fundamentals
GKOS
JNJ
—
Trailing P/E
26.3×
293.1×
Forward P/E
17.9×
-34.3%
Profit Margin
21.8%
78.1%
Gross Margin
68.0%
-26.4%
ROE
26.4%
41.2%
Revenue Growth
9.9%
—
Earnings Growth
-52.9%
0.78
Beta
0.33
—
Price / Book
—
$8.2B
Market Cap
$546.9B
$73 – $147
52-Week Range
$146 – $252
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →